Kymera Therapeutics
OverviewSuggest Edit
Kymera Therapeutics is a biotechnology company aimed to create medicines for patients with previously untreatable diseases. The company specializes in the field of targeted protein degradation (TPD) accessing the body’s innate protein recycling machinery to degrade rather than inhibit dysregulated, disease-causing proteins. Its proprietary integrated degradation platform, Pegasus, consists of informatics-driven target identification, novel E3 ligases, proprietary ternary complex predictive modeling capabilities and degradation tools.
| Type | Private | |
| Founded | 2017 | |
| HQ | Watertown, MA, US | Map |
| Website | kymeratx.com |
Recent NewsAll News
- Kymera Therapeutics Announces Fourth Quarter and Full Year 2020 Financial Results and Provides a Business Update
- Kymera Therapeutics Announces First-in-Human Dose in Phase 1 Trial of KT-474, a First-in-Class IRAK4 Protein Degrader to Treat Immune-Inflammatory Diseases
- Kymera Therapeutics to Present at Upcoming March Investor Conferences
- Kymera Therapeutics to Present at Upcoming February Investor Conferences
Key People/Management at Kymera Therapeutics
Nello Mainolfi
Founder, President, Chief Executive Officer & Director
Jared Gollob
Chief Medical Officer
Bruce Jacobs
Chief Financial Officer
Richard Chesworth
Chief Scientific Officer
Brian Albarran
Vice President, Strategy and Operations
Paige Cochran
Vice President, Human Resources
Kymera Therapeutics Office Locations
Kymera Therapeutics has an office in Watertown
Watertown, MA, US (HQ)
200 Arsenal Yards Blvd #230
Kymera Therapeutics Financials and Metrics
Summary Metrics
Founding Date | 2017 |
Kymera Therapeutics total Funding | $197 m |
Kymera Therapeutics latest funding size | $102 m |
Time since last funding | a year ago |
Kymera Therapeutics investors | BlackRock, Atlas Venture, Bessemer Venture Partners, Wellington Management, Redmile Group, Lilly Ventures, Pfizer Venture Investments, Amgen Ventures, Aju IB Investment, Hatteras Venture Partners, Rock Springs Capital, Biotechnology Value Fund, Sanofi-Genzyme BioVentures, Bain Capital Life Sciences, 6 Dimensions Capital, Janus Henderson Investors, MRL Ventures Fund |
Kymera Therapeutics's latest funding round in March 2020 was reported to be $102 m. In total, Kymera Therapeutics has raised $197 m
Kymera Therapeutics Cybersecurity Score
Kymera Therapeutics Online and Social Media Presence
1.95k Twitter followers
Kymera Therapeutics has 1.95k Twitter Followers. The number of followers has increased 3.2% month over month and increased 6.6% quarter over quarter
Kymera Therapeutics's Trends
Twitter Engagement Stats for @KymeraTx
429
Tweets
121
Following
1.9k
Followers
20
Tweets last 30 days
8.5
Avg. likes per Tweet
100%
Tweets with engagement
Kymera Therapeutics News and Updates
March 11, 2021
Kymera Therapeutics Announces Fourth Quarter and Full Year 2020 Financial Results and Provides a Business Update
Initiated Phase 1 first-in-human dosing of KT-474, a first-in-class oral IRAK4 degrader to treat immune-inflammatory diseases
March 02, 2021
Kymera Therapeutics Announces First-in-Human Dose in Phase 1 Trial of KT-474, a First-in-Class IRAK4 Protein Degrader to Treat Immune-Inflammatory Diseases
KT-474 is the first IRAK4 degrader, and first heterobifunctional small molecule protein degrader outside of oncology, to enter clinical development
February 25, 2021
Kymera Therapeutics to Present at Upcoming March Investor Conferences
WATERTOWN, Mass., Feb. 25, 2021 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein degrader medicines, today announced that the Company will participate in upcoming investor confer…
February 04, 2021
Kymera Therapeutics to Present at Upcoming February Investor Conferences
WATERTOWN, Mass., Feb. 04, 2021 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein degrader medicines, today announced that the Company will present at two upcoming investor confer…
February 03, 2021
Kymera Therapeutics Strengthens Leadership with Key Appointments and Promotions
WATERTOWN, Mass., Feb. 03, 2021 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein degrader medicines, today announced the appointments of Ashwin Gollerkeri, MD, as Senior Vice Pre…
January 05, 2021
Kymera Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference on Thursday, January 14, 2021
WATERTOWN, Mass., Jan. 05, 2021 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein degrader medicines, today announced that the Company will present at the virtual 39th Annual J.P.…
Kymera Therapeutics Blogs
April 10, 2021
American Association of Cancer Research (AACR) 2021 Annual Meeting, April 10-15, 2021
Poster Presentation: Mechanisms Underlying Synergistic Activity of KT-413, a Targeted Degrader of IRAK4 and IMiD Substrates in Hematopoietic Cancers
The post American Association of Cancer Research (AACR) 2021 Annual Meeting, April 10-15, 2021 appeared first on Kymera Therapeutics.
February 16, 2021
Oxford Global’s Virtual Symposium: Targeted Protein Degradation & PROTAC, February 16-17, 2021
Poster Presentation: Discovery of Potent and Selective STAT3 Targeted Protein Degraders with Excellent in vitro and in vivo ADME Properties
The post Oxford Global’s Virtual Symposium: Targeted Protein Degradation & PROTAC, February 16-17, 2021 appeared first on Kymera Therapeutics.
February 16, 2021
2nd Annual North American Protein Degradation Congress, February 16-24, 2021
Poster Presentation: Targeted Protein Degradation in Oncology and Beyond
The post 2nd Annual North American Protein Degradation Congress, February 16-24, 2021 appeared first on Kymera Therapeutics.
December 07, 2020
62nd American Society of Hematology (ASH) Virtual Annual Meeting and Exposition, December 5-8, 2020
Poster Presentation: Targeting MYD88-Mutant DLBCL with IRAKIMiDs: A Comparison to IRAK4 Kinase Inhibition and Evaluation of Synergy with Rational Combinations
The post 62nd American Society of Hematology (ASH) Virtual Annual Meeting and Exposition, December 5-8, 2020 appeared first on Kymera Therape…
December 01, 2020
Becoming CEO: The First 18 Months
I’ve held many titles and even more roles at Kymera since founding the company with Bruce Booth and Atlas Venture four years ago. But it’s been just over 12 months since we announced my appointment to CEO, and nearly 18 months in the role. Looking back now, I could not imagine a more challenging and…
November 04, 2020
IRAK4 Degrader to Take on Innate Immunity, November 3, 2020
Mullard, A. IRAK4 degrader to take on innate immunity. Nat Biotechnol 38, 1221–1223 (2020). https://doi.org/10.1038/s41587-020-0724-8
The post IRAK4 Degrader to Take on Innate Immunity, November 3, 2020 appeared first on Kymera Therapeutics.
Kymera Therapeutics Frequently Asked Questions
When was Kymera Therapeutics founded?
Kymera Therapeutics was founded in 2017.
Who are Kymera Therapeutics key executives?
Kymera Therapeutics's key executives are Nello Mainolfi, Jared Gollob and Bruce Jacobs.
How many employees does Kymera Therapeutics have?
Kymera Therapeutics has 86 employees.
Who are Kymera Therapeutics competitors?
Competitors of Kymera Therapeutics include Foghorn Therapeutics, Urovant Sciences and Praxis Precision Medicines.
Where is Kymera Therapeutics headquarters?
Kymera Therapeutics headquarters is located at 200 Arsenal Yards Blvd #230, Watertown.
Where are Kymera Therapeutics offices?
Kymera Therapeutics has an office in Watertown.
How many offices does Kymera Therapeutics have?
Kymera Therapeutics has 1 office.
Learn about Craft real-time company insights
Receive alerts for 300+ data fields across thousands of companies